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Abstract 
 
Background: Inflammatory cytokines have been known to be associated with Chronic 
Heart Failure (CHF). Given the importance of cytokines in the context of the failing 
heart, the prevalence of Interleukin-2 (IL-2) and Interferon-gamma (IFN-γ) poly-
morphisms was studied in patients with CHF due to ischemic heart disease in a case-
control study.  
 
Methods: Fifty-six Iranian patients with CHF were enrolled in this study as the case 
group and compared with 139 healthy subjects, using polymerase chain reaction with 
sequence-specific primers method, so as to determine the frequency of alleles, geno-
types and haplotypes of IFN-γ (+874 A/T) and IL-2 (-330 G/T, +166 G/T) SNPs.  
 
Results: The GG genotype at IL-2 -330 in patients with CHF was significantly over-
represented in comparison with the control group (p=0.013). Such a positive genotypic 
association was also observed for IL-2 +166/TT (p=0.022). Meanwhile, the GT genotype 
frequency at IL-2 -330/GT in the patient group was significantly lower than the one in 
healthy controls (p=0.049). No significant association was detected between the IFN-γ 
gene polymorphisms and individuals’ susceptibility to CHF.  
 
Conclusion: Certain genotypes in IL-2 gene were overrepresented in patients with 
CHF, which could render individuals more vulnerable to this disease.  
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Introduction 
 
Chronic Heart Failure (CHF) is a serious clinical 
condition, characterized by impaired contractile func-
tion and progressive ventricular dilation 1. As with any 
other major health issue, CHF greatly influences the 
quality of life of patients with this condition; therefore, 
it stands to reason that introduction of promising future 
genetic markers which could affect individual prone-
ness to this disease, seems essential to initiate therapy 
in advance. 
 
 
 
 
Various etiologies such as hypertension, coronary 
artery disease and infection, result in heart failure. Dif-
ferent heart failure models indicate the roles of cyto-
kines, as major actors in different immune mecha-
nisms, in the aforementioned etiologies leading to CHF 
2-4. Interleukin-2 (IL-2) is one such proinflammatory 
cytokine, which induces proliferation of T cells 5. The 
other cytokine of this category is Interferon-gamma 
(IFN-γ), which is mainly produced by Natural Killer 
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(NK) cells and T cells. This cytokine is known to be 
associated with T helper 1 (Th1) responses 6. Previous 
investigations have indicated the importance of these 
two inflammatory cytokines, IL-2 and IFN-γ, in the 
etiopathogenesis of various conditions such as athero-
sclerosis and ischemic and non-ischemic dilated cardi-
omyopathy, which could stand as the underlying cause 
of CHF development 7-9.  
It has been postulated that Single Nucleotide Poly-
morphisms (SNPs) within coding and promoter se-
quences of cytokine genes could affect their secretion 
pattern 10,11. Numerous studies have been performed on 
cytokine gene polymorphisms in the context of various 
immunological disorders 12-20. However, due to the 
paucity of data regarding the contribution of cytokines’ 
gene polymorphisms in CHF susceptibility, achieving 
consensus seems impossible so far. To the best of our 
knowledge, this is the first study to explore certain IL-2 
and IFN-γ gene polymorphisms in Iranian patients with 
CHF. 
This study was conducted in a group of Iranian pa-
tients with CHF in order to assess the associations of 
SNPs in IL-2 at positions -330 and +166 as well as 
IFN-γ at position +874 with the disease.  
 
Materials and Methods 
 
Subjects 
Fifty-six Iranian patients with CHF (42 males, 14 
females) with the mean age of 57.96±12.24 years were 
enrolled in this study. Diagnosis of CHF in patients 
was based on intensive history taking, thorough physi-
cal examination, electrocardiography and impaired Left 
Ventricular (LV) systolic function (LV ejection frac-
tion ≤40%) and LV dilation (LV end-diastolic diameter 
>5.5 cm) on echocardiography. Subjects with recent 
myocardial infarction, malignancies, chronic lung dis-
ease and acute decompensated HF within 3 months 
before enrollment, were excluded from the study. Only 
those patients in stable clinical condition, who had re-
ceived conventional medical therapy for at least 3 
months, were enrolled in this study. Baseline demo-
graphic and clinical characteristics of patients with 
CHF, included in the current study, are depicted in 
table 1. One hundred and thirty nine unrelated healthy 
subjects (mean age 45.63±10.84; 100 men, 39 women) 
who were randomly selected from blood donors at Ira-
nian blood transfusion organizations, were also select-
ed as the control group 21. This study was approved by 
the Ethics Committee of Tehran University of Medical 
Sciences. Written informed consent was obtained from 
all participants prior to sampling. 
 
Genotyping 
After DNA extraction from the peripheral blood 
leukocytes using the "salting out" technique 22, the pol-
ymerase chain reaction, with sequence-specific primers 
(PCR-SSP assay kit; Heidelberg University, Germany) 
was employed for cytokine gene typing 21. Briefly, 
amplification of the extracted gene was performed by a 
Techne Flexigene thermal cycler (Roche) under the 
following conditions: initial denaturation at 94°C for 2 
min; denaturation at 94°C for 10 s; annealing+exten-
sion at 65°C for 1 min (10 cycles); denaturation at 
94°C for 10 s; annealing at 61°C for 50 s; and exten-
sion at 72°C for 30 s (20 cycles). Subsequently, the 
availability of the Polymerase Chain Reaction (PCR) 
products was assessed using 2% agarose gel electro-
phoresis. Thereafter, the gel was placed on an Ultravio-
let (UV) transilluminator, and a picture was taken for 
analysis and documentation. The frequencies of alleles, 
genotypes and haplotypes of IL-2 (G/T at -330 and 
+166) and IFN-γ (A/T at -+874) were counted. 
 
Statistical analysis 
Allele, genotype and haplotype frequencies were 
calculated by direct gene counting. In order to test the 
Hardy-Weinberg equilibrium, the frequencies of vari-
ous genotypes were compared using the chi square test. 
The odds ratios and 95% Confidence Intervals (CI) 
were estimated for each allele, genotype and haplotype. 
A p-value of less than 0.05 was considered significant. 
 
Results 
 
Alleles, genotype and haplotype frequencies 
The allelic and genotype frequencies in patients 
with CHF and healthy controls are depicted in table 2. 
The GG genotype at IL-2 -330 in patients with CHF 
was significantly increased in comparison with the 
control group [p=0.013, OR=3.56, 95%CI: 1.32-9.57]. 
Such a positive genotypic association was also observ-
ed for IL-2 +166/TT [p=0.022, OR=6.72, 95% CI: 
1.26-35.71]. Meanwhile, the GT genotype frequency at 
IL-2 -330 in the patient group was significantly lower 
than the one in healthy controls [p=0.049, OR=0.51, 
Table 1. Baseline demographic and clinical characteristics of 
patients with CHF 
 
Variables N (%) 
Age (year)±SD 57.96±12.24 
Sex (male) (%) 43 (75.4%) 
Hypertension 21 (36.8%) 
Diabetes 19 (36.8%) 
Dyslipidemia 22 (38.6%) 
Obesity 8 (14%) 
History of smoking  
    Current smoker 25 (43.9%) 
    Ex-smoker 4 (7%) 
    Non-smoker 28 (49.1%) 
History of ACS 31 (54.4%) 
COPD 4 (7%) 
Chronic kidney disease 5 (8.8%) 
Liver disease 2 (3.5%) 
Cerebrovascular accident 1 (1.8%) 
History of CABG 5 (8.8%) 
History of PCI 4 (7%) 
NYHAA classification  
I 15 (26.3%) 
II 18 (31.6%) 
III 15 (26.3%) 
IV 9 (15.8%) 
 
COPD, Chronic Obstructive Pulmonary Disease; CABG, Coronary Rrtery 
Bypass Grafting; PCI, Percutaneous Coronary Intervention. 
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95%CI: 0.27-0.97]. On the other hand, no significant 
association was found between the IFN-γ gene poly-
morphisms at +874 position and individuals’ vulnera-
bility to CHF. 
No significant differences were found between the 
two groups for GG, TG, TT and GT haplotypes at posi-
tions -330 and +166 of IL-2 gene (Table 3). 
 
Discussion 
 
Several pieces of evidence have shown that inflam-
mation is an important actor in cardiovascular diseases, 
including Left Ventricular Dysfunction (LVD) and 
subsequent heart failure, which constitutes an ultimate 
common pathway for a multitude of cardiac disorders 
23,24. Recently, the potential role of circulating inflam-
matory markers, such as IL-2 and IFN-γ, as risk predic-
tors of cardiovascular events has been a topic of inten-
sive research 25. It has long been speculated that cyto-
kine gene polymorphisms could affect their serum lev-
el, as discussed in advance. Therefore, considering the 
significance of inflammation in cardiac diseases, the 
present study was designed to examine a sample of 
Iranian patients with CHF for the SNPs in IFN-γ gene 
at position +874 as well as IL-2 polymorphisms at po-
sitions -330 and +166. 
IL-2 is a secretory cytokine generated by activated T 
lymphocytes, which induces T cells, B cells, and NK 
cells to proliferate and produce other cytokines 26. Re-
ports have suggested IL-2 as a predictor of vascular 
disease 7. Recent studies have proposed that elevated 
levels of IL-2 indicate intensified T cell response to 
different antigens, which are assumed to be critical in 
the promotion of atherosclerosis 7,8. Previous studies 
have suggested the IL-2 G allele at position -330 is 
associated with enhanced IL-2 expression. IL-2 (-330) 
GG genotype is recognized as a polymorphism with an 
increased level of cytokine production following anti-
CD3/CD28 stimulation of lymphocytes. However, the 
GT genotype at the same position is acknowledged as a 
genotype with an intermediate level of IL-2 gene ex-
pression. IL-2 (-330) TT genotype is also known to 
cause low IL-2 levels 27. Our statistical analysis of IL-2 
gene polymorphisms disclosed increased frequency of 
IL-2 -330 GG genotype as well as IL-2 +166 TT 
genotype in patient group, compared with control cate-
gory, while IL-2 -330 GT genotype was shown to be 
more frequent in healthy controls. Our results are con-
sistent with the findings of a recent study conducted by 
Ding et al 28, which revealed the association of IL-2  
-330 GG genotype with increased risk of coronary ar-
tery disease. Their results also showed that subjects 
carrying IL-2 -330 GG genotype had increased serum 
level of IL-2 in comparison with those with TG or TT 
genotypes 28. 
IFN-γ is a proinflammatory cytokine produced by 
Th1 cells, which enhances the expression of MHC 
Table 2. IL-2 and IFN-γ allele and genotype polymorphisms in Iranian patients with CHF and controls 
 
Cytokine Position Alleles/Genotypes Controls (n=139) N (%) Patients (n=56) N (%) Odds Ratio (95% CI) p-value 
IL-2 
-330 
G 110 (39.6) 49 (43.7) 1.19 (0.76-1.85) 0.495 
T 168 (60.4) 63 (56.3)   
GG 8 (5.8) 10 (17.9) 3.56 (1.32-9.57) 0.013 
GT 94 (67.6) 29 (51.8) 0.51 (0.27-0.97) 0.049 
TT 37 (26.6) 17 (30.3) 1.2 (0.61-2.38) 0.600 
+166 
G 219 (78.8) 80 (71.4) 0.67 (0.41-1.11) 0.145 
T 59 (21.2) 32 (28.6)   
GG 82 (59) 29 (51.8) 0.75 (0.4-1.39) 0.425 
GT 55 (39.6) 22 (39.3) 0.99 (0.52-1.86) 1 
TT 2 (1.4) 5 (9) 6.72 (1.26-35.71) 0.022 
   N=138 N=51   
  A 140 (50.7) 49 (48) 0.89 (0.57-1.41) 0.728 
  T 136 (49.3) 53 (52)   
IFN-γ +874 AA 43 (31.2) 12 (23.5) 0.68 (0.32-1.43) 0.369 
  AT 54 (39.1) 25 (49) 1.5 (0.78-2.86) 0.247 
  TT 41 (29.7) 14 (27.5) 0.89 (0.44-1.83) 0.858 
 
Table 3. IL-2 haplotype polymorphism in Iranian patients with CHF and controls 
 
Cytokine Position Haplotype Controls (n=138) N (%) 
Patients (n=56) 
N (%) Odds ratio (95% CI) p-value 
IL-2 -330, +166 
GG 107 (38.8) 46 (41.1) 1.1 (0.7-1.72) 0.731 
TG 112 (40.6) 34 (30.3) 0.64 (0.4-1.02) 0.065 
TT 56 (20.3) 29 (25.9) 1.37 (0.82-2.3) 0.226 
GT 1 (0.3) 3 (2.7) 7.57 (0.78-73.56) 0.074 
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class I and class II molecules. An increment of IFN-γ-
positive CD4 (+) T cells has been previously reported 
in patients with CHF 6. On the contrary, diminishment 
in IFN-γ serum levels has been described 29, in a group 
of patients with CHF secondary to ischemic and non-
ischemic dilated cardiomyopathy. Several investiga-
tions have demonstrated the expression of IFN-γ in the 
immunological activation of atherosclerotic lesions 
from both clinical samples together within preclinical 
mouse atherosclerosis models 9,30. Among multitude of 
SNPs reported in IFN-γ gene, IFN-γ +874 A/T poly-
morphism, which maps to the putative Nuclear Factor-
kB (NF-kB) binding site is known to enhance the ex-
pression of IFN-γ gene, where A mutant allele is pre-
sent, while the presence of T allele is known to be in-
volved in underexpression of IFN-γ 31. Multiple studies 
carried out in both humans and rodent models have 
investigated a proatherogenic role of IFN-γ 32-35. Garg 
et al 36 suggested a significant role of IFN-γ +874 T 
allele in the occurrence of coronary heart disease. In 
the current investigation, no association was found 
between polymorphisms in IFN-γ at position +874 and 
individual susceptibility to CHF. 
This study has certain limitations that should be 
acknowledged. Firstly, our limitations to measure the 
serum levels of IL-2 and IFN-γ hindered evaluation of 
the relevance of gene variants in terms of cytokine lev-
els in patients with CHF. Additionally, previous studies 
performed in this field have not resulted in a consensus 
regarding the aforementioned cytokines’ serum levels 
in patients with CHF, as some have reported elevated 
levels of IL-2 and IFN-γ in patients with CHF, while 
some others have suggested decreased levels of these 
cytokines in such patients. These contradictory results 
warrant further analysis of Il-2 and IFN-γ levels in 
CHF. Moreover, the relatively small number of our 
subjects could diminish the statistical power of our 
analysis. 
 
Conclusion 
 
To conclude, it is suggested that certain single nu-
cleotide polymorphisms in IL-2 gene can affect the risk 
of developing CHF. These associations may help us 
define both predisposing and protective genetic mark-
ers with regard to CHF. However, in order to delineate 
the role of IFN-γ and IL-2 genotypes in the pathogene-
sis of CHF and influence on IFN-γ and IL-2 produc-
tion, further studies on cytokine gene polymorphisms 
in other populations, using larger sample size, are re-
quired. 
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